Lataa...
Lapatinib Activates the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in HepG2 Cells
The receptor tyrosine kinase inhibitor lapatinib, indicated to treat patients with HER2-positive breast cancer in combination with capecitabine, can cause severe hepatotoxicity. Lapatinib is further associated with mitochondrial toxicity and accumulation of reactive oxygen species. The effect of lap...
Tallennettuna:
| Julkaisussa: | Front Pharmacol |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7339965/ https://ncbi.nlm.nih.gov/pubmed/32694997 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.00944 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|